HCM240517C22500
- 0.50
- 0.000.00%
Hutchmed (China) Newsroom
[Broker Focus] BOC International is optimistic about the recovery trend of overall investment sentiment in the pharmaceutical industry in 2Q/2H
Jinwu Financial News | BOC International said that recently, the US announced an increase in taxes on low-value consumables such as syringes, ranging from 0% to 50%. Considering that the gross margin of low-value consumables is generally low, the bank believes that a drastic tax increase will reduce the competitiveness of some Chinese products exported to the US market. In terms of sector allocation ideas, the bank is optimistic about the recovery trend of overall investment sentiment in the pharmaceutical industry in 2Q/2H, but the segment may continue to diverge. It is recommended to focus on leaders in major fields such as weight loss/NASH, medical equipment updates, pharmaceutical device innovation going overseas (new technology path/platform), reading significant data on innovative drugs, state-owned enterprise reform+high dividends
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Hutchmed (China) Chairman Resigns, Successor Named
Hutchmed (China) (HKG:0013) said its chairman of the board of directors, Simon To, stepped down and will be succeeded by Dan Eldar, according to a Friday filing on the Hong Kong bourse. Price (HKD): $
[Broker Focus] BOC International's first purchase rating for 5 biotech companies indicates that it is firmly optimistic about the sector's potential for heavy snow
Jinwu Financial News | BOC International released an in-depth report on the biotechnology industry. In 2024, the State Council government work report first proposed speeding up the development of the innovative pharmaceutical industry, building new types of productivity such as biomantry, and encouraging entrepreneurship and equity investment. The bank believes that it will continue to introduce supporting policies in the future to promote the development momentum of pharmaceutical innovation. The bank believes that the sector has opportunities for valuation repair within 2024, mainly considering: 1) there has been a large degree of disconnection in the past year, and the bank is optimistic about the chances of Hong Kong stocks recovering compared to US stocks; 2) important overseas events such as overseas licensing/mergers and acquisitions transactions are expected to continue to be implemented in 2024.
HUTCHMED's Breakthroughs in Hematology Spotlighted
Hutchmed (China) Chairman Simon To Resign; Dan Eldar Appointed Chairman
By Chris Wack Hutchmed (China) said Friday that Simon To has resigned as chairman and executive director and that Dan Eldar has been named as the company's new chairman effective immediately. The co
HUTCHMED Appoints New Chairman Amid Board Changes
HUTCHMED to Present Promising Study Results at EHA2024
Hehuang Pharmaceutical (00013.HK): Will announce data on the 2024 European Hematology Association (EHA) ESLIM-01 phase III study and hematological malignancy project data
Gelonghui, May 17丨Hewang Pharmaceutical (00013.HK) announced today that it will announce the top line and subgroup results of the solepinib ESLIM-01 phase III study, as well as the latest and updated clinical data on innovative exploratory hematologic malignancy therapies HMPL-306, HMPL-760, and tazostat (tazostemetat) at the European Hematology Association (“EHA”) annual meeting to be held in Madrid and online from June 13 to June 16, 2024.
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association ("EHA") Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
Analysts' Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
Reported Earlier, HUTCHMED Initiates The RAPHAEL Registrational Phase III Trial Of HMPL-306 For Patients With IDH1- And/Or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia In China
HMPL-306 is a novel dual-inhibitor of IDH1 and IDH2 enzymes. Mutations of IDH1 and IDH2 have been implicated as drivers of certain hematological malignancies, gliomas and solid tumors, particularly am
Express News | Reported Earlier, HUTCHMED Initiates Phase II/III Trial Of The Combination Of Surufatinib And Camrelizumab For Treatment-Naïve Pancreatic Ductal Adenocarcinoma In Collaboration With Hengrui
[Broker Focus] Guotai Junan maintains Hewang Pharmaceutical's (00013) “increase” rating and is optimistic that furoquintinib will further open up overseas markets
Jin Wu Financial News | According to Symphony Health data, sales of Hewang Pharmaceutical (00013) fruquintinib in US medical institutions (including US hospitals, doctors' clinics, long-term medical institutions, etc.) have increased month-on-month since launch 2023.11-2024.03 to reach 1.44/5.18/10.31/13.30/15.33 million US dollars, respectively (258%/99%/29%/15% month-on-month increase): Miquintinib is accelerating in the US, in the future, along with Europe and The Japanese market has been approved, and the bank expects
HUTCHMED Trials New Therapy for Pancreatic Cancer
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3%
Hutchmed (HKG:0013) started its phase 2/3 trial for the combination of surufatinib and camrelizumab in patients with metastatic pancreatic ductal adenocarcinoma in China, according to a Tuesday filing
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China
Hutchmed (HKG:0013) began its phase 3 trials for the HMPL-306 drug in patients with mutated isocitrate dehydrogenase 1 or 2 relapsed or refractory acute myeloid leukemia in China, according to a Tuesd
Hehuang Pharmaceutical (00013.HK): Initiating a RAPHAEL registered phase III study on HMPL-306 in the treatment of relapsed/refractory acute myeloid leukemia patients with IDH1 and/or IDH2 mutations in China
On May 14, Ge Longhui Pharmaceutical (00013.HK) announced today the launch of a registered phase clinical trial of HMPL-306 to treat relapsed/refractory acute myeloid leukemia (AML) with isocitrate dehydrogenase (“IDH”) 1 or 2 mutations in China. The first test subject received the first dose of medication on May 11, 2024.
Hehuang Pharmaceutical (00013.HK) and Hengrui Pharmaceutical reached a cooperation and initiated a phase II/III study on surufatinib (surufatinib) combined with camrelizumab (camrelizumab) in the treatment of primary pancreatic ductal adenocarcinoma
Gelonghui, May 14, 丨 Hehuang Pharmaceutical (00013.HK) announced the launch of a Chinese phase II/III clinical trial today to evaluate Hehuang Pharmaceutical's drug candidate surufatinib (surufatinib), the PD-1 antibody camrelizumab (camrelizumab) of Jiangsu Hengrui Pharmaceutical Co., Ltd. (“Hengrui Pharmaceutical”), albumin-conjugated paclitaxel (nab-paclitaxel), and gemcitabine (gemcitabine) for first-line treatment of metastatic pancreatic conduction Ductal adenocarcinoma (PDAC) patients
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients With IDH1- And/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase ("IDH") 1 or 2 relapsed / refractory acute myeloid leukemia ("AML") in China. The first patient received their first dose on May 11, 2024.